Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04775082 | SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity | PHASE3 | ACTIVE NOT_RECRUITING | 78 | — | — | Mar 4, 2021 | Feb 8, 2027 | May 22, 2026 | 32 | United States, Belgium +7 |
| NCT02647944 | Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity | PHASE2 | COMPLETED | 40 | — | — | Dec 18, 2015 | Dec 30, 2016 | Oct 27, 2017 | 1 | United States |
| NCT07225816 | Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | PHASE1 | RECRUITING | 75 | — | — | Nov 7, 2025 | Jul 17, 2026 | Jan 23, 2026 | 1 | United States |
Percent
Gastric emptying of solids was assessed by scintigraphy using a 320 Kcal 99mTc-radiolabeled egg, solid-liquid meal. Gastric Emptying Half-time was the linear interpretation of time to when 50% of radiolabeled meal emptied from the stomach.
Gastric emptying of solids was assessed by scintigraphy using a 320 Kcal 99mTc-radiolabeled egg, solid-liquid meal. Gastric Emptying Half-time was the linear interpretation of time to when 50% of radiolabeled meal emptied from the stomach.
Measured as count of participants.
Measured as count of participants.
Measured as count of participants.
| Arm | Type | Description |
|---|---|---|
| Liraglutide 3.0 mg | EXPERIMENTAL | The treatment duration is 56 weeks and the follow-up period is 26 weeks. |
| Placebo | PLACEBO_COMPARATOR | The treatment duration is 56 weeks and the follow-up period is 26 weeks. |
| Liraglutide | ACTIVE_COMPARATOR | Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication. |
| Oral semaglutide | EXPERIMENTAL | Participants will receive semaglutide orally. |
| Semaglutide | EXPERIMENTAL | Participants will receive semaglutide subcutaneously. |
| Name | Type | Description |
|---|---|---|
| Liraglutide | DRUG | The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily. The dose will increase each week over 4 or 5 weeks until the final dose is reached. |
| Placebo | DRUG | The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily. |
| Oral Semaglutide | DRUG | Participants will receive semaglutide orally. |
| Semaglutide | DRUG | Participants will receive semaglutide subcutaneously. |
Inclusion Criteria: * Informed consent of parent(s) or legally acceptable representative of subject and child assent, as age-appropriate, obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to dete...